PwHD HD-ISS Stages 2 and 3 and HC participants who:
- Are currently participating in, or are less than 30 days after completing participation in, other therapeutic or imaging studies.
- Have previously participated in a PET imaging study in the past 12 months that, cumulatively with the current study, will exceed annual regulatory limits for radiation exposure.
- Have any disease, condition, or concomitant medication that significantly compromises the function of the body systems and that, in the opinion of the Investigator, might interfere with the conduct of the study or its interpretation.
- Are pregnant and breastfeeding females.
- Have concomitant use of antiplatelet or anticoagulant therapy (inclusive of acetylsalicylic acid).
- Have a bleeding disorder.
- Have a needle phobia.
- Have any metal objects present in the body that are incompatible with MRI.
- Have metal objects present in the body that are compatible with MRI and are located in the head or neck.
Have any clinically significant results on safety laboratory tests that, in the opinion of the Investigator, would either put the participant at risk or interfere with the conduct of the study or interpretation of data. These tests include, but are not limited to:
- a. positive results for HBsAg, HepC, HIV-1 or HIV-2 (will also be reported as required by local/national regulations),
- b. clinically significant, abnormal results for safety laboratory tests.
PwHD participants who:
If they are using any antidepressant, psychoactive, psychotropic or other medications or nutraceuticals used to treat HD, the use of inappropriate (e.g., non-therapeutically high) or unstable dose within 30 days prior to participation.
HC participants who:
- Have a family history of HD and have not been tested for the huntingtin gene (CAG) expansion.
